What is this summary about?This summary describes early (not final) results of a clinical study called CHOICE-01. The study looked at the effect of a medicine called toripalimab when added to standard chemotherapy (chemicals used to stop the growth of or kill cancer cells) for adults with untreated non-small cell lung cancer (NSCLC) without driver mutations (i.e. EGFR/ALK mutations excluded from the study) that was classified as locally advanced or had spread to other parts of the body (metastatic NSCLC). Researchers wanted to see whether toripalimab added to standard chemotherapy was safe and effective for increasing the amount of time adults with untreated advanced NSCLC not suitable for surgery could live without their cancer getting worse (a measurement called ‘progression-free survival’), and living longer (a measurement called “overall survival”).What are the key takeaways?Results from the CHOICE-01 study showed that adults with advanced inoperable NSCLC treated with toripalimab plus standard chemotherapy had significantly longer progression-free survival than those who received standard chemotherapy alone. Early results for overall survival, a measurement of how long patients lived overall, also demonstrated significantly better results in the group treated with toripalimab. The treatment groups with and without toripalimab had similar rates of side effects (effects of a medicine that are beyond its desired effect that can be harmful), which were tracked to assess safety.What were the main conclusions reported by the researchers?The results of the CHOICE-01 study showed that patients with advanced NSCLC treated with toripalimab plus chemotherapy had longer progression-free survival and overall survival than those who received chemotherapy alone. These results support the addition of toripalimab to chemotherapy for adults with untreated advanced NSCLC without driver mutations.Who is this summary for?This summary is intended to provide information to adults with advanced NSCLC and their family members or caregivers. It may also be helpful for patient advocates and healthcare professionals.[Box: see text].